Business
Lineage Cell Therapeutics Issues Letter to Stockholders
CARLSBAD, Calif., January 05, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, today published a letter to shareholders highlighting the company’s achievements throughout 2025 and its corporate outlook for 2026.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/cf9c54df807790ce41b8625e6a54b3c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SX1azUADceOXwTBjLREn3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cf9c54df807790ce41b8625e6a54b3c9","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IhgpmF429FajSrDMF3XaXA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cf9c54df807790ce41b8625e6a54b3c9","width":1200,"height":248}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., January 05, 2026--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, today published a letter to shareholders highlighting the company’s achievements throughout 2025 and its corporate outlook for 2026.","length":394,"tagName":"p"},{"type":"text","content":"To Our Shareholders:","length":20,"tagName":"p"},{"type":"text","content":"As we conclude a successful 2025, I want to extend my appreciation for your continued support of Lineage Cell Therapeutics and our mission to pioneer the emerging field of allogeneic cell therapy. I also wish to provide an outline for how we plan to continue our success in 2026.","length":279,"tagName":"p"},{"type":"text","content":"The field of cell therapy has revolutionized oncology, saving lives and creating substantial shareholder value. But opportunities to build on success in that field appear increasingly difficult or marginal. We believe the next frontier of value-creation in cell therapy resides in non-oncology indications, such as neurology, ophthalmology, and metabolic diseases. We also believe Lineage is uniquely positioned to capitalize on this opportunity, mainly by applying our proprietary cell manufacturing technology to the production and transplantation of differentiated cell types.","length":579,"tagName":"p"},{"type":"text","content":"Lineage is helping usher in this new branch of medicine by demonstrating the value of administering mature, differentiated cells, w...